Financial reports
10-Q
2024 Q3
Quarterly report
11 Mar 24
10-Q
2024 Q2
Quarterly report
7 Dec 23
10-Q
2024 Q1
Quarterly report
7 Sep 23
ARS
2023 FY
Annual report to shareholders
14 Aug 23
10-K
2023 FY
Annual report
7 Jul 23
10-Q
2023 Q3
Quarterly report
9 Mar 23
10-Q
2023 Q2
Quarterly report
8 Dec 22
10-Q
2023 Q1
Quarterly report
8 Sep 22
10-K
2022 FY
Annual report
7 Jul 22
10-Q
2022 Q3
Quarterly report
10 Mar 22
Current reports
8-K
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
22 Apr 24
8-K
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
11 Mar 24
8-K
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
7 Mar 24
8-K
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
16 Feb 24
8-K
Termination of a Material Definitive Agreement
14 Feb 24
8-K
Regulation FD Disclosure
13 Feb 24
8-K
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
7 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
28 Sep 23
8-K
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
7 Sep 23
8-K
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
7 Jul 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
S-8
Registration of securities for employees
9 Jan 24
S-8
Registration of securities for employees
20 Jun 23
S-8
Registration of securities for employees
10 Jan 23
424B5
Prospectus supplement for primary offering
27 Dec 22
S-8
Registration of securities for employees
10 Mar 22
S-8
Registration of securities for employees
13 Jul 21
S-3
Shelf registration
21 May 21
S-8
Registration of securities for employees
11 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
14 Aug 23
DEF 14A
Definitive proxy
14 Aug 23
PRE 14A
Preliminary proxy
4 Aug 23
DEFA14A
Additional proxy soliciting materials
11 Oct 22
DEFA14A
Additional proxy soliciting materials
22 Aug 22
DEF 14A
Definitive proxy
22 Aug 22
DEFA14A
Additional proxy soliciting materials
17 Aug 21
DEF 14A
Definitive proxy
17 Aug 21
DEF 14A
Definitive proxy
25 Aug 20
DEF 14A
Definitive proxy
23 Aug 19
Other
EFFECT
Notice of effectiveness
2 Jun 21
UPLOAD
Letter from SEC
27 May 21
CORRESP
Correspondence with SEC
27 May 21
EFFECT
Notice of effectiveness
24 Dec 18
CORRESP
Correspondence with SEC
20 Dec 18
UPLOAD
Letter from SEC
20 Dec 18
CT ORDER
Confidential treatment order
13 Mar 18
EFFECT
Notice of effectiveness
28 Apr 17
CORRESP
Correspondence with SEC
27 Apr 17
CORRESP
Correspondence with SEC
26 Apr 17
Ownership
4
William Fairey
22 Apr 24
3
William Fairey
22 Apr 24
SC 13D/A
TCG Crossover GP I, LLC
1 Apr 24
4
Benjamin L Palleiko
8 Mar 24
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
26 Feb 24
4
Bong Y Koh
22 Feb 24
SC 13D/A
Frazier Life Sciences Public Fund, L.P.
22 Feb 24
4
Edward P. Feener
21 Feb 24
4
Christopher Yea
21 Feb 24
4
Benjamin L Palleiko
21 Feb 24